March 15, 2021
Takeda Pharmaceutical said on March 12 that it has filed a new drug application in Japan for lanadelumab, a monoclonal antibody therapy for prophylaxis against attacks of hereditary angioedema (HAE). The Japanese drug giant is seeking the nod for lanadelumab...read more